Literature DB >> 28079928

Relation of serum and vitreous nesfatin-1 concentrations with diabetic retinopathy.

Rongfeng Dai1, Guohua Deng2, Zhuo Sun2, Zhinan Liu2, Yu Qian1, Yan Han1.   

Abstract

OBJECTIVE: Nesfatin-1, belonging to adipokine family, serves as an anti-inflammatory mediator. We performed this investigation to evaluate the relation between serum and vitreous nesfatin-1 concentrations with diabetic retinopathy (DR).
METHODS: This study was performed in a population of 189 diabetic patients and 48 control subjects. Diabetic patients were then divided into diabetic patients without DR, non-proliferative diabetic retinopathy (NPDR) patients, and proliferative diabetic retinopathy (PDR) patients.
RESULTS: Serum and vitreous nesfatin-1 concentrations were significantly lower in the diabetic patients than in the controls. NPDR patients had reduced vitreous nesfatin-1 concentrations compared with patients without DR. In addition, there were significantly lower serum and vitreous nesfatin-1 concentrations in PDR patients compared with the other three groups. Pearson correlation analysis showed that serum nesfatin-1 was negatively correlated with body mass index and fasting plasma glucose in diabetic patients.
CONCLUSION: Serum and vitreous nesfatin-1 concentrations were negatively correlated with DR.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  angiogenesis; diabetic retinopathy; inflammation; nesfatin-1

Mesh:

Substances:

Year:  2017        PMID: 28079928      PMCID: PMC6817133          DOI: 10.1002/jcla.22105

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  22 in total

Review 1.  Diabetic retinopathy.

Authors:  Donald S Fong; Lloyd P Aiello; Frederick L Ferris; Ronald Klein
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

2.  Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet β- and MIN6 cells.

Authors:  Ronald Gonzalez; Benjamin K Reingold; Xiaodong Gao; Mandeep P Gaidhu; Robert G Tsushima; Suraj Unniappan
Journal:  J Endocrinol       Date:  2011-01-11       Impact factor: 4.286

3.  Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects.

Authors:  Matteo Riva; Marloes Dekker Nitert; Ulrikke Voss; Ramasri Sathanoori; Andreas Lindqvist; Charlotte Ling; Nils Wierup
Journal:  Cell Tissue Res       Date:  2011-11-23       Impact factor: 5.249

4.  Influence of bariatric surgery on the expression of nesfatin-1 in rats with type 2 diabetes mellitus.

Authors:  Zefeng Xia; Geng Wang; Huiqing Li; Chaojie Hu; Qingbo Wang; Anshu Li; Ende Zhao; Xiaoming Shuai; Jiliang Wang; Kailin Cai; Kaixiong Tao; Guobin Wang
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

5.  Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism.

Authors:  H Shimizu; S Oh-I; K Hashimoto; M Nakata; S Yamamoto; N Yoshida; H Eguchi; I Kato; K Inoue; T Satoh; S Okada; M Yamada; T Yada; M Mori
Journal:  Endocrinology       Date:  2008-10-16       Impact factor: 4.736

Review 6.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.

Authors:  C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

7.  The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain.

Authors:  Chong-Hui Tang; Xiao-Jun Fu; Xin-Long Xu; Xiao-Jie Wei; Hong-Song Pan
Journal:  Peptides       Date:  2012-04-24       Impact factor: 3.750

8.  Nesfatin-1 improves oxidative skin injury in normoglycemic or hyperglycemic rats.

Authors:  Ali Solmaz; Elif Bahadır; Osman B Gülçiçek; Hakan Yiğitbaş; Atilla Çelik; Ayça Karagöz; Derya Özsavcı; Serap Şirvancı; Berrak Ç Yeğen
Journal:  Peptides       Date:  2016-01-30       Impact factor: 3.750

9.  Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease.

Authors:  Shimei Ding; Wei Qu; Shuangsuo Dang; Xuan Xie; Jing Xu; Yuhuan Wang; Aiyu Jing; Chunhong Zhang; Junhong Wang
Journal:  Med Sci Monit       Date:  2015-04-04

10.  Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus.

Authors:  Fupeng Liu; Qing Yang; Ning Gao; Fangfang Liu; Shaohua Chen
Journal:  J Diabetes Res       Date:  2014-06-04       Impact factor: 4.011

View more
  6 in total

1.  Islet β-cell-produced NUCB2/nesfatin-1 maintains insulin secretion and glycemia along with suppressing UCP-2 in β-cells.

Authors:  Yifei Yang; Boyang Zhang; Masanori Nakata; Jun Nakae; Masatomo Mori; Toshihiko Yada
Journal:  J Physiol Sci       Date:  2019-06-21       Impact factor: 2.781

Review 2.  Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Authors:  Ting Zhai; Shi-Zhen Li; Xin-Tong Fan; Zhao Tian; Xiao-Qing Lu; Jing Dong
Journal:  J Diabetes Res       Date:  2017-12-28       Impact factor: 4.011

3.  The Variation and Correlation of Serum Adiponectin, Nesfatin-1, IL-6, and TNF-α Levels in Prediabetes.

Authors:  Kangkang Huang; Yunlai Liang; Yating Ma; Jiahui Wu; Huidan Luo; Bin Yi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-03       Impact factor: 5.555

4.  Influence of circulating nesfatin-1, GSH and SOD on insulin secretion in the development of T2DM.

Authors:  Kangkang Huang; Yunlai Liang; Kun Wang; Jiahui Wu; Huidan Luo; Bin Yi
Journal:  Front Public Health       Date:  2022-08-15

5.  Protective role and molecular mechanism of action of Nesfatin-1 against high glucose-induced inflammation, oxidative stress and apoptosis in retinal epithelial cells.

Authors:  Haiyan Sun; Huahui Zhao; Zhipeng Yan; Xiaokun Liu; Pengfei Yin; Jun Zhang
Journal:  Exp Ther Med       Date:  2021-06-03       Impact factor: 2.447

6.  NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population.

Authors:  Xue-Song Li; Chen-Yan Yan; Yu-Juan Fan; Jia-Lin Yang; Shuang-Xia Zhao
Journal:  Ann Transl Med       Date:  2020-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.